polycystin 1 like 3, transient receptor potential channel interactingGenealiases: []
Q-omics provides the consensus-scored PKD1L3 profile across patient tissues and cancer cell-line models. PKD1L3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PKD1L3 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, PKD1L3 RNA expression shows 16,061 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, COAD, and UVM as cancer lineages where PKD1L3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PKD1L3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PKD1L3 survival associations across molecular data types. PKD1L3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PKD1L3 RNA expression–survival associations across cancer types. High PKD1L3 expression shows unfavorable associations in KIRC, LGG and LUSC, but favorable associations in MESO, PAAD and SKCM. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for PKD1L3 RNA expression.
This table summarizes PKD1L3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for PKD1L3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PKD1L3 shows lower tumor expression in BRCA and higher tumor expression in COAD, KIRC, STAD, READ and PRAD. The COAD box plot shows higher PKD1L3 RNA expression in tumor versus normal tissue (log2 FC = +0.133, t-test p = .005).
This table shows molecular features associated with PKD1L3 in patient tissues and cancer cell lines. In patient samples, PKD1L3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PKD1L3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and OVARY.
